论文部分内容阅读
为探讨急性白血病（ＡＬ）患者多药耐药相关蛋白（ＭＲＰ）基因表达与ＦＡＢ亚型及免疫表型的关系，应用半定量逆转录－多聚酶链反应技术检测了５４例ＡＬ患者ＭＲＰ基因的表达。以正常人或非恶性血液病患者的单个核细胞为对照组。发现临床耐药组ＭＲＰ基因表达（中位数１．１８）高于完全缓解（ＣＲ）组（中位数０．２２，Ｐ＝０．０６５９）。ＡＬ各组ＭＲＰ基因表达均明显高于对照组（中位数０）。ＭＲＰ基因表达与白血病ＦＡＢ亚型无关。ＣＤ１３＋与ＣＤ１３－组ＭＲＰ基因表达有显著性差异（Ｐ＝０．００２９），而与其它细胞免疫表型无关。根据ＭＲＰ基因表达在ＡＬ各组的分布，将ＭＲＰ与β２微球蛋白之比大于１．０定为ＭＲＰ＋，临床耐药组ＭＲＰ＋占６６．６７％，明显高于ＣＲ组（２０％，Ｐ＝０．０２１３）
To investigate the relationship between multidrug resistance-related protein (MRP) gene expression and FAB subtypes and immunophenotype in patients with acute leukemia (AL), the expression of MRP gene in 54 AL patients was detected by semi-quantitative reverse transcription polymerase chain reaction . Mononuclear cells from normal or non-hematologic malignant patients served as control group. It was found that MRP gene expression (median 1.18) was higher in the clinically resistant group than in the complete remission (CR) group (median 0.22, P = 0.0659). The expression of MRP gene in AL group was significantly higher than that in control group (median 0). MRP gene expression and leukemia FAB subtypes has nothing to do. The expression of MRP gene in CD13 + and CD13- groups was significantly different (P = 0.0029), but not with other cellular phenotypes. According to the distribution of MRP gene in AL group, the ratio of MRP to β2 microglobulin was greater than 1.0, and MRP + was 66.67% in clinical drug resistance group, which was significantly higher than that in CR group (20%, P = 0.0213)